Brief: Icosavax Announces Positive Topline Interim Phase 2 Results For Combination VLP Vaccine Candidate IVX-A12 Against RSV And HMPV In Older Adults

Icosavax

12/12/2023 07:03

Dec 12 (Reuters) - Icosavax Inc  ICVX.O :
    * ICOSAVAX ANNOUNCES POSITIVE TOPLINE INTERIM PHASE 2
RESULTS FOR
COMBINATION VLP VACCINE CANDIDATE IVX-A12 AGAINST RSV AND HMPV
IN OLDER ADULTS
    * ICOSAVAX - IVX-A12 INDUCED ROBUST IMMUNE RESPONSES AT DAY
28 TO
RSV & HMPV, WAS GENERALLY WELL TOLERATED, CONSISTENT WITH PRIOR
IVX-A12 PHASE 1 DATA
    * ICOSAVAX - TOPLINE INTERIM SAFETY AND IMMUNOGENICITY DATA
FROM
THIS TRIAL WERE GENERALLY CONSISTENT WITH PREVIOUSLY REPORTED
PHASE 1 DATA FOR IVX-A12

Source text for Eikon:  ID:nGNX4KzBYS 
Further company coverage:  ICVX.O 

 ((Reuters.Briefs@thomsonreuters.com;))